Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07470489 · ClinicalTrials.gov registry record · Phase 2
Zanzalintinib Plus Cemiplimab for the Treatment of BRAF Wild-Type Anaplastic Thyroid Cancer
A Phase 2 study, sponsored by M.D. Anderson Cancer Center.
- Not yet
- Registry status
- Phase 2
- Development phase
- 12
- Enrollment target
NCT07470489: Clinical Trial Phase 2 study, sponsored by M.D. Anderson Cancer Center.
NCT07470489 is a Phase 2 study that has not yet begun recruiting, run by M.D. Anderson Cancer Center. The registered enrollment target is 12 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07470489, a Phase 2 study, has not yet begun recruiting, sponsored by M.D. Anderson Cancer Center.
- NOT YET RECRUITING
- Registry status
- Phase 2
- Development phase
- 12 participants
- Enrollment target
Study Summary
The goal of the trial is to improve this OS by 4 months (to 9.9 months) using the zanzalintinib + cemiplimab treatment combination. Given an accrual period of 24 months and a maximum follow-up time of 36 months, at the significance level of 0.1, to achieve the power of 0.8, the sample size needed is 24 patients and the number of events required is 17. These results are based on a one-sided test with exponential assumption for survival time.
Interventions
- DRUG Cemiplimab
- DRUG Zanzalintinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2026-09-30 |
| Est. Completion | 2032-09-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07470489
The ClinicalTrials.gov registry entry for NCT07470489 describes a study currently listed as not yet recruiting, categorized as Phase 2. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Cemiplimab is the first listed.
NCT07470489 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07470489 about?
NCT07470489 is a clinical study titled "Zanzalintinib Plus Cemiplimab for the Treatment of BRAF Wild-Type Anaplastic Thyroid Cancer". The goal of the trial is to improve this OS by 4 months (to 9.9 months) using the zanzalintinib + cemiplimab treatment combination. Given an accrual period of 24 months and a maximum follow-up time of 36 months, at the significance level of 0.1, to achieve the power of 0.8, the sample size needed is...
What is the current status of trial NCT07470489?
This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 2026-09-30. Estimated completion is 2032-09-01.
What interventions are being tested in trial NCT07470489?
The interventions under investigation include: Cemiplimab (DRUG), Zanzalintinib (DRUG).
Who is sponsoring clinical trial NCT07470489?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.